Gil Blum, Ph.D., joined Needham & Company’s Biotech research team in August 2017. Gil joined Needham from Cadwalader Wickersham & Taft, New York oldest law firm where he was a Scientific Advisor in intellectual property law and prosecution. Prior to Cadwalader, Gil held a postdoctoral fellowship at the Memorial-Sloan Kettering Cancer Center, developing early drug candidates. Gil holds a Doctoral degree in Chemical Biology from Cornell University and a B.Sc. in Chemistry from Tel-Aviv University.